Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8291 in Post-Herpetic Neuralgia
NCT02336555Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of MK-8291 in postherpetic neuralgia (PHN) (2 arms), sponsored by Merck & Co. Primary endpoint: Change From Baseline in Pain Intensity at Week 4 of Each Treatment Period. Started Mar 2015; status: completed.
02
Drugs
MK-8291
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT02336555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336555.